| Old Articles: <Older 3261-3270 Newer> |
|---|
 |
The Motley Fool
November 7, 2006
Brian Lawler |
Abraxis Advances The drug developer's platform technology could improve existing drugs, much to investors' excitement.   |
The Motley Fool
November 7, 2006
Michael P. Cecil |
Will a 10-Bagger Go Higher? Cambridge Heart has a special EKG machine that helps determine which patients need defibrillators. The stock is up tenfold in the past 12 months. After results of a major trial are announced, will the share price go higher? |
The Motley Fool
November 6, 2006
Matthew Crews |
Smith & Nephew Is Hip to Growth The medical technology company is showing solid growth, but a possible acquisition is cause for concern. Investors, take note. |
The Motley Fool
November 6, 2006
Brian Gorman |
Novartis' China Gambit Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore. Investors, take note. |
The Motley Fool
November 6, 2006
Brian Lawler |
Neurocrine's Big Headache Another clinical trial means a steep drop in share price, but the biopharmaceutical's not dead yet. Investors, take note. |
The Motley Fool
November 6, 2006
Brian Lawler |
The Impending Verdict on Momenta The drug developer isn't willing to wait for potential legislation on generic drugs. Investors, take note. |
The Motley Fool
November 6, 2006
Ralph Casale |
Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam. |
Chemistry World
November 3, 2006
Richard Van Noorden |
Antimatter Cancer Treatment Researchers working at Cern's particle accelerator laboratory have just reported a successful first experiment into the biological effects of antiproton radiation on living cells. A US biotech firm already owns the intellectual property rights on the development of an antiproton clinic. |
The Motley Fool
November 3, 2006
Brian Lawler |
Nothing's Wrong With ViroPharma Despite potential generic competition on the horizon, the company is going strong. Vancocin's fate will determine how well shares of ViroPharma perform in the near future. |
The Motley Fool
November 2, 2006
Brian Lawler |
BioMarin's in Good Health This biopharma has a leg up on the competition by getting its finances in order. Even with its small pipeline, BioMarin appears to be running smoothly. Investors, take note. |
| <Older 3261-3270 Newer> Return to current articles. |
